Moderna has reported its first quarter results, with revenue exceeding estimates, partly due to stronger international covid vaccine sales. However, the company's earnings were impacted by a litigation charge, leading to mixed results. The reports do not consistently indicate how the market has reacted to the news, with some outlets focusing on the company's performance in relation to other therapeutics stocks.